Add to favorite
World health care and pharmaceuticals were not ready for coronavirus infection. There was a shortage of doctors, hospital beds, medicines, and an understanding of how to fight the new virus successfully. The states redesigned hospitals, built new ones, involved doctors of almost any specialization and even medical students in the treatment of patients, in pharmaceuticals the race for drugs against the new virus and vaccines began. What is happening has significantly increased the interest of investors in the industry, including in Russia. In the first Forbes rating "20 best pharmaceutical companies in Russia", only domestic drug manufacturers are represented, their total revenue in 2019 reached 285 billion rubles, which is almost 70 billion rubles more than a year earlier. The growth leader in 2019 was Skopinpharm (325%), followed by ESG Biotech (182%). Only one company - Valenta Pharm (minus 7%) showed negative dynamics.
The first place in the rating was taken by Alexey Repik's R-Pharm F 48, which received the maximum number of points in terms of revenue and profit for 2019. The second is Biocad, co-owned by Viktor Kharitonin F 43. This company scored the maximum number of points in terms of the number of approvals issued to it for conducting clinical trials. Both companies are in the race to develop a vaccine against COVID-19 - preparing production sites for its serial production. Whoever launches vaccine production first will receive a guaranteed and long-term contract from the state for tens of billions of rubles. Not everyone can decide to do this in Russian pharmaceuticals - there are very few companies that can be classified as high-tech. Domestic production of medicines is mainly the release of generics (copies of original medicines for which the patent has expired). According to the marketing agency DSM Group, in the first half of 2020, generics accounted for more than 63% of retail drug sales in rubles and almost 84% in packs.
The pandemic has shown another weakness of Russian pharmaceuticals - almost complete dependence of domestic industries on imported substances. In Russia, only 15% of substances are produced, the rest is imported from abroad. In 2019, $ 1.8 billion was spent on this, substances were mainly imported from China (20% of supplies), France (17%) and India (10.5%). The pandemic and the related closure of borders almost left the Russian pharmaceutical industry without the main components of drug production. The stocks of substances made before the introduction of drug labeling in the country and the rapid return of the main supplying countries to world trade were rescued.
The state, most likely, will in every possible way stimulate the creation of high-tech pharmaceutical companies and production facilities for the production of domestic substances. However, Russian pharmaceuticals are not deprived of attention anyway. In 2019, the Russian pharmaceutical market was estimated at 1.8 trillion rubles, 560 billion rubles of which, according to DSM Group, provided government procurement (24% more than in 2018, the entire market grew by 9.5%). The state spent almost 310 billion rubles on the purchase of medicines for medical institutions, and the main beneficiary of this process was Biocad, which earned 19.6 billion rubles on hospital purchases.
Calculations
The rating includes leading Russian drug manufacturers. The long list includes the largest companies in terms of revenue for 2019, which in the SPARK system are classified as the “Production of drugs and materials used for medical purposes” industry. The list of companies controlled by private individuals (more than 50%) does not include Russian enterprises of global conglomerates. The companies were assessed according to five criteria using the weighting method: revenue for 2019 (weight 40%, maximum score - 40), change in revenue for the year (10%), net profit (30%), number of drugs registered (10%) and the number of approvals issued to conduct clinical trials (10%). The financial results were collected in the SPARK system, registration of medicines and permission to conduct clinical trials - in the State Register of Medicines (data as of August 5, 2020). For the final result, the points for all parameters are summed up, companies are ranked by their sum. The maximum possible total score is 100.
The first place in the rating was taken by Alexey Repik's R-Pharm F 48, which received the maximum number of points in terms of revenue and profit for 2019. The second is Biocad, co-owned by Viktor Kharitonin F 43. This company scored the maximum number of points in terms of the number of approvals issued to it for conducting clinical trials. Both companies are in the race to develop a vaccine against COVID-19 - preparing production sites for its serial production. Whoever launches vaccine production first will receive a guaranteed and long-term contract from the state for tens of billions of rubles. Not everyone can decide to do this in Russian pharmaceuticals - there are very few companies that can be classified as high-tech. Domestic production of medicines is mainly the release of generics (copies of original medicines for which the patent has expired). According to the marketing agency DSM Group, in the first half of 2020, generics accounted for more than 63% of retail drug sales in rubles and almost 84% in packs.
The pandemic has shown another weakness of Russian pharmaceuticals - almost complete dependence of domestic industries on imported substances. In Russia, only 15% of substances are produced, the rest is imported from abroad. In 2019, $ 1.8 billion was spent on this, substances were mainly imported from China (20% of supplies), France (17%) and India (10.5%). The pandemic and the related closure of borders almost left the Russian pharmaceutical industry without the main components of drug production. The stocks of substances made before the introduction of drug labeling in the country and the rapid return of the main supplying countries to world trade were rescued.
The state, most likely, will in every possible way stimulate the creation of high-tech pharmaceutical companies and production facilities for the production of domestic substances. However, Russian pharmaceuticals are not deprived of attention anyway. In 2019, the Russian pharmaceutical market was estimated at 1.8 trillion rubles, 560 billion rubles of which, according to DSM Group, provided government procurement (24% more than in 2018, the entire market grew by 9.5%). The state spent almost 310 billion rubles on the purchase of medicines for medical institutions, and the main beneficiary of this process was Biocad, which earned 19.6 billion rubles on hospital purchases.
Calculations
The rating includes leading Russian drug manufacturers. The long list includes the largest companies in terms of revenue for 2019, which in the SPARK system are classified as the “Production of drugs and materials used for medical purposes” industry. The list of companies controlled by private individuals (more than 50%) does not include Russian enterprises of global conglomerates. The companies were assessed according to five criteria using the weighting method: revenue for 2019 (weight 40%, maximum score - 40), change in revenue for the year (10%), net profit (30%), number of drugs registered (10%) and the number of approvals issued to conduct clinical trials (10%). The financial results were collected in the SPARK system, registration of medicines and permission to conduct clinical trials - in the State Register of Medicines (data as of August 5, 2020). For the final result, the points for all parameters are summed up, companies are ranked by their sum. The maximum possible total score is 100.
Sources: https://www.forbes.ru
Author: Anna Dorozhkina
